drugset
drugset / Trial / NCT02975271

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

NCT02975271 ↗

Phase 2 Terminated 1 enrolled Vyne Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of the Efficacy, Safety \& Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

Timeline

Start
2016-11
Primary completion
2017-01-17
Completion
2017-01-17

Outcome

Outcome not reported

Stopped (Business): “Business Reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject Serlopitant Small molecule — —

Indications

No indication recorded.